# Telix Pharmaceuticals Ltd: overview TLX · Nasdaq · CIK 2007191 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/tlx.md) · [Financials](/companies/tlx/financials.md) · [Filings](/companies/tlx/filings.md) · [Insiders](/companies/tlx/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY (2023-12-31) | FY (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | | Revenue | $m | [333](/filings/0001628280-26-009943.md) | [517](/filings/0001628280-26-009943.md) | [804](/filings/0001628280-26-009943.md) | | Gross margin | % | [62.9%](/filings/0001628280-26-009943.md) | [65.1%](/filings/0001628280-26-009943.md) | [53.1%](/filings/0001628280-26-009943.md) | | Operating margin | % | [3.3%](/filings/0001628280-26-009943.md) | [10.7%](/filings/0001628280-26-009943.md) | [3.7%](/filings/0001628280-26-009943.md) | | Net margin | % | [1.3%](/filings/0001628280-26-009943.md) | [6.5%](/filings/0001628280-26-009943.md) | [(0.9%)](/filings/0001628280-26-009943.md) | | Diluted EPS | $ per share | [0.01](/filings/0001628280-26-009943.md) | [0.10](/filings/0001628280-26-009943.md) | [(0.02)](/filings/0001628280-26-009943.md) | | Free cash flow | $m | [8.0](/filings/0001628280-26-009943.md) | [18.4](/filings/0001628280-26-009943.md) | [(43.0)](/filings/0001628280-26-009943.md) | - Revenue. XBRL Revenue: ifrs-full:Revenue. - Gross margin (gross profit / revenue). XBRL Gross profit: ifrs-full:GrossProfit; Revenue: ifrs-full:Revenue. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:Revenue. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLossAttributableToOwnersOfParent; Revenue: ifrs-full:Revenue. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/tlx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $6.5m | 561,206 | | Reduced −3,551 | | [LAZARD ASSET MANAGEMENT LLC](/funds/1207017.md) | 2026-06-30 | $3.3m | 284,207 | | Reduced −5,710 | | [PORTLAND INVESTMENT COUNSEL INC.](/funds/1081668.md) | 2026-06-30 | $3.1m | 266,200 | | Unchanged | | [Private Advisor Group, LLC](/funds/1567755.md) | 2026-06-30 | $2.3m | 197,250 | | Added +22,835 | | [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $2.2m | 189,188 | | New +189,188 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $1.9m | 165,978 | | Added +49,538 | | [Integrated Wealth Concepts LLC](/funds/1737109.md) | 2026-06-30 | $1.9m | 164,397 | | Unchanged | | [Hennion & Walsh Asset Management, Inc.](/funds/1861642.md) | 2026-06-30 | $1.7m | 150,138 | | New +150,138 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $1.6m | 134,698 | | Added +102,398 | | [BLAIR WILLIAM & CO/IL](/funds/902367.md) | 2026-06-30 | $1.4m | 122,985 | | New +122,985 | ## Recent filings [All 109 filings](/companies/tlx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-29 | 16:52 ET | [6-K](/filings/0001628280-26-068291.md) | Report of a foreign private issuer, period 2026-10-29 | 0001628280-26-068291 | | 2026-10-21 | 19:40 ET | [6-K](/filings/0001628280-26-066581.md) | Report of a foreign private issuer, period 2026-10-21 | 0001628280-26-066581 | | 2026-09-30 | 20:19 ET | [6-K](/filings/0001628280-26-063875.md) | Report of a foreign private issuer, period 2026-09-30 | 0001628280-26-063875 | | 2026-09-21 | 08:55 ET | [6-K](/filings/0001628280-26-062813.md) | Report of a foreign private issuer, period 2026-09-21 | 0001628280-26-062813 | | 2026-09-14 | 16:52 ET | [6-K](/filings/0001628280-26-061892.md) | Report of a foreign private issuer, period 2026-09-14 | 0001628280-26-061892 | | 2026-09-02 | 20:30 ET | [6-K](/filings/0001628280-26-059952.md) | Report of a foreign private issuer, period 2026-09-02 | 0001628280-26-059952 | | 2026-09-01 | 20:39 ET | [6-K](/filings/0001628280-26-059684.md) | Report of a foreign private issuer, period 2026-09-01 | 0001628280-26-059684 | | 2026-08-20 | 21:48 ET | [6-K](/filings/0001628280-26-058126.md) | Report of a foreign private issuer, period 2026-06-30 | 0001628280-26-058126 | | 2026-07-21 | 07:06 ET | [6-K](/filings/0001628280-26-048922.md) | Report of a foreign private issuer, period 2026-06-30 | 0001628280-26-048922 | | 2026-07-02 | 16:27 ET | [6-K](/filings/0001628280-26-046936.md) | Report of a foreign private issuer, period 2026-07-01 | 0001628280-26-046936 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-009943.md), filed Feb 20, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 2007191 - Tickers: TLX, TLPPF - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: C3 - Filer category: Large accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:54 ET. No prices; not investment advice.